<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04764058</url>
  </required_header>
  <id_info>
    <org_study_id>210</org_study_id>
    <nct_id>NCT04764058</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Colistin Based Antibiotic Therapy</brief_title>
  <official_title>Efficacy and Safety of Colistin Based Antibiotic Therapy for Multidrug Resistant Gram Negative Infections in Pediatric Intensive Care Unit</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of antibiotic combinations containing Colistin in the&#xD;
      treatment of children with multidrug-resistant gram negative infections admitted in the&#xD;
      pediatric surgery intensive care unit.&#xD;
&#xD;
      The main outcome measure is clinical and microbiological responses to therapy.&#xD;
&#xD;
      The secondary outcome is the occurrence of adverse events during Colistin combination&#xD;
      treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients and Methods&#xD;
&#xD;
      Design of the study:&#xD;
&#xD;
      - Prospective, Randomized, interventional study.&#xD;
&#xD;
      Setting:&#xD;
&#xD;
      - The study will be conducted in the pediatric surgery intensive care unit in Children's&#xD;
      Hospitals, Ain Shams University, Cairo, Egypt.&#xD;
&#xD;
      Subjects:&#xD;
&#xD;
      - Pediatric patients admitted in pediatric surgery intensive care unit.&#xD;
&#xD;
      Inclusion criteria:&#xD;
&#xD;
      All children with culture-proven nosocomial infections due to multidrug resistance&#xD;
      gram-negative organisms&#xD;
&#xD;
      Exclusion criteria:&#xD;
&#xD;
        1. Patients who started on Colistin treatment outside the pediatric surgery intensive care&#xD;
           unit and transferred to the unit afterward will be excluded.&#xD;
&#xD;
        2. Patients who will receive &lt;6 doses of intravenous Colistin will be excluded.&#xD;
&#xD;
        3. Patients received Imipenem or Colistin-Imipenem compination as empirical antibiotic.&#xD;
&#xD;
      Methodology:&#xD;
&#xD;
      - Sixty pediatric patients admitted to the pediatric surgery intensive care unit will be&#xD;
      enrolled in the study and will be randomly assigned to either Group I or Group II&#xD;
&#xD;
      Group I: Thirty patients will receive IV Colistin in dosages of 50,000-75,000 IU/kg/day in&#xD;
      three divided doses, infused IV in 10mL normal saline over 30 minutes with IV Imipenem in&#xD;
      doses of 15 to 25 mg/kg every 6 hours¬.21,22,24 Colistin formulation consists of 2 million IU&#xD;
      per vial. Group II: Thirty patients will receive IV Imipenem in doses of 15 to 25 mg/kg every&#xD;
      6 hours¬. 22,24&#xD;
&#xD;
      For all patients the following data will be collected:&#xD;
&#xD;
        1. Demographic data (age, gender, weight).&#xD;
&#xD;
        2. The risk factors for nosocomial infections.&#xD;
&#xD;
        3. Pediatric surgery intensive care unit stay.&#xD;
&#xD;
        4. Type of surgeries performed.&#xD;
&#xD;
        5. Site of isolation of organisms.&#xD;
&#xD;
        6. The dose and duration of therapy.&#xD;
&#xD;
        7. Serum creatinine levels will be assessed at baseline, once weekly and at the end of&#xD;
           Colistin combination therapy.&#xD;
&#xD;
        8. Nephrotoxic co-medication monitoring.&#xD;
&#xD;
        9. Clinical (resolution of signs and symptoms of infection) and&#xD;
&#xD;
       10. microbiological (bacteriologic responses) outcomes will be evaluated during treatment&#xD;
           and at the end of the treatment.&#xD;
&#xD;
      According to the inclusion and exclusion criteria, the demographic data for the intended ICU&#xD;
      patients was collected, then the sample was withdrawn from the infected site to be cultured&#xD;
      on specific culture media (such as blood agar, MacConkey agar, Chocolate agar), and&#xD;
      identification of the isolated microorganism was detected by biochemical tests and Vitek-2&#xD;
      compact system whenever required. Antimicrobial sensitivity to Colistin was tested using the&#xD;
      micro broth dilution method, in order to be evaluated in Colistin therapy. After&#xD;
      culture-proven, the drug was given, either IV Colistin-Imipenem/Cilastatin as a combination&#xD;
      or Imipenem/Cilastatin as a monotherapy. Throughout this step, the hemodynamic parameters&#xD;
      were measured during the process of treatment, without neglecting the serum creatinine level&#xD;
      to detect any nephrotoxicity.&#xD;
&#xD;
      We assure the right drug handling, dosing, dispensing, and monitoring. At the end of the&#xD;
      treatment, the duration and length of PICU stay were recorded.&#xD;
&#xD;
      The decision and/or conclusion of treatment failure and/ or success was based upon the&#xD;
      worsening and/or improvement of the patients' parameters and their situation including the&#xD;
      results of the microbiological examination before and after the intervention&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">September 1, 2017</start_date>
  <completion_date type="Anticipated">September 1, 2021</completion_date>
  <primary_completion_date type="Actual">September 1, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemodynamic Parameters Measurement ,heart beating rate.</measure>
    <time_frame>2 year</time_frame>
    <description>the efficacy and safety of antibiotic combination containing Colistin. We will monitor the heart beating rate.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemodynamic Parameters Measurement ,body temperature</measure>
    <time_frame>2 year</time_frame>
    <description>the efficacy and safety of antibiotic combination containing Colistin. We will monitor the body temperature</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemodynamic Parameters Measurement ,respiratory rate.</measure>
    <time_frame>2 year</time_frame>
    <description>the efficacy and safety of antibiotic combination containing Colistin. We will monitor the respiratory rate.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemodynamic Parameters Measurement ,blood pressure</measure>
    <time_frame>2 year</time_frame>
    <description>the efficacy and safety of antibiotic combination containing Colistin. We will monitor the blood pressure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemodynamic Parameters Measurement ,partial oxygen saturation pressure</measure>
    <time_frame>2 year</time_frame>
    <description>the efficacy and safety of antibiotic combination containing Colistin. We will monitor the partial oxygen saturation pressure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemodynamic Parameters Measurement and Septic Markers, serum lactate</measure>
    <time_frame>2 year</time_frame>
    <description>the efficacy and safety of antibiotic combination containing Colistin. We will monitor the serum lactate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemodynamic Parameters Measurement ,serum creatinine</measure>
    <time_frame>2 year</time_frame>
    <description>the efficacy and safety of antibiotic combination containing Colistin. We will monitor the serum creatinine</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Septicemia</condition>
  <condition>Bacterial Infections</condition>
  <arm_group>
    <arm_group_label>Montherapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Thirty patients will receive IV Imipenem in doses of 15 to 25 mg/kg every 6 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Thirty patients will receive IV Colistin in dosages of 50,000-75,000 IU/kg/day in three divided doses, infused IV in 10mL normal saline over 30 minutes with IV Imipenem in doses of 15 to 25 mg/kg every 6 hours¬.21,22,24 Colistin formulation consists of 2 million IU per vial.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tienam 500</intervention_name>
    <description>Imipenem and cilastatin sodium</description>
    <arm_group_label>Combination</arm_group_label>
    <arm_group_label>Montherapy</arm_group_label>
    <other_name>Meronem</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Infusion</intervention_name>
    <description>Health caregivers give the drug to the patients and monitoring the infusion rate</description>
    <arm_group_label>Combination</arm_group_label>
    <arm_group_label>Montherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All children with culture proven nosocomial infections due to multidrug resistance&#xD;
             gram-negative organisms&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Patients who started on Colistin treatment outside the pediatric surgery intensive&#xD;
             care unit and transferred to the unit afterward will be excluded.&#xD;
&#xD;
             2. Patients who will receive &lt;6 doses of intravenous Colistin will be excluded.&#xD;
&#xD;
             3. Patients received Imipenem or Colistin-Imipenem compination as empirical&#xD;
             antibiotic.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AHMED S ATTIA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heliopolis University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ain Shams Univesity Hospital</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 15, 2021</study_first_submitted>
  <study_first_submitted_qc>February 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2021</study_first_posted>
  <last_update_submitted>February 18, 2021</last_update_submitted>
  <last_update_submitted_qc>February 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Ahmed Saeed Attia Mancy</investigator_full_name>
    <investigator_title>Pharmacist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Bacterial Infections</mesh_term>
    <mesh_term>Sepsis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cilastatin, Imipenem Drug Combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

